Skip to content Skip to footer
Viewpoints_Dr. Robert Rifikin

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots: There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity  Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]